For how we live.
A test-negative study across seven paediatric hospitals in Ontario and Quebec, run after a publicly funded rollout, estimated 78% effectiveness against laboratory-confirmed RSV and 97% against intensive-care admission.
A Spanish registry followed 166 patients with treatment-resistant epileptic encephalopathies for a year. Median seizure frequency fell 68.8%, though the design cannot match a placebo-controlled trial.
Gastric bypass patients lost roughly 28% of body weight at three years, against 7-11% for tirzepatide or semaglutide — even among patients who stayed on the drugs continuously for at least a year.
Switzerland allows limited psilocybin use for treatment-resistant depression. A review of 19 patients found meaningful improvement, but remission in barely a fifth to a quarter.
A single-clinic retrospective study in Istanbul followed patients on all three drugs for 36 weeks. The ranking matches what randomized trials have shown — with liraglutide the least tolerated of the three.
Head-to-head in US insurance data, the two drugs showed comparable cardiovascular outcomes and comparable rates of severe gastrointestinal events in type 2 diabetes. Neither study was a trial.